Long-term risk for major bleeding during extended oral anticoagulant therapy for first unprovoked venous thromboembolism: a systematic review and meta-analysis
Background: The long-term risk for major bleeding in patients receiving extended (beyond
the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous …
the initial 3 to 6 months) anticoagulant therapy for a first unprovoked venous …
Estimating quality of life in acute venous thrombosis
Importance Future funding for new treatments in venous thromboembolism will be guided
by cost-utility analyses. There is little available information on the utility of acute venous …
by cost-utility analyses. There is little available information on the utility of acute venous …
[HTML][HTML] Long‐term risk of recurrent venous thromboembolism among patients receiving extended oral anticoagulant therapy for first unprovoked venous …
Background The long‐term risk for recurrent venous thromboembolism (VTE) during
extended anticoagulation for a first unprovoked VTE is uncertain. Objectives To determine the …
extended anticoagulation for a first unprovoked VTE is uncertain. Objectives To determine the …
Anticoagulation management and related outcomes in patients with cancer-associated thrombosis and thrombocytopenia: a systematic review and meta-analysis
Background Patients with cancer have an increased risk of both venous thromboembolism (VTE)
requiring anticoagulation and thrombocytopenia. The optimal management is unclear. …
requiring anticoagulation and thrombocytopenia. The optimal management is unclear. …
Apixaban for the prevention of venous thromboembolism in high-risk ambulatory cancer patients receiving chemotherapy: rational and design of the AVERT trial
Patients with active cancer have a heightened risk of venous thromboembolism (VTE). This
risk is further increased by the initiation of chemotherapy. Although previous studies have …
risk is further increased by the initiation of chemotherapy. Although previous studies have …
Cost–utility analysis of apixaban compared with usual care for primary thromboprophylaxis in ambulatory patients with cancer
Background: Apixaban (2.5 mg) taken twice daily has been shown to substantially reduce
the risk of venous thromboembolism (VTE) compared with placebo for the primary …
the risk of venous thromboembolism (VTE) compared with placebo for the primary …
Risk of major bleeding during extended oral anticoagulation in patients with first unprovoked venous thromboembolism: a systematic review and meta-analysis …
Background The optimal duration of anticoagulation after a first unprovoked venous
thromboembolism (VTE) remains controversial. Deciding to stop or continue anticoagulant therapy …
thromboembolism (VTE) remains controversial. Deciding to stop or continue anticoagulant therapy …
What's new in the prevention and treatment of cancer-associated thrombosis?
M Kimpton, M Carrier - Hematology 2014, the American Society …, 2019 - ashpublications.org
Venous thromboembolism (VTE) is a common complication in ambulatory cancer patients
receiving chemotherapy. Current clinical guidelines recommend against the use of routine …
receiving chemotherapy. Current clinical guidelines recommend against the use of routine …
Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism
M Kimpton, M Carrier - Expert Opinion on Drug Safety, 2019 - Taylor & Francis
Introduction: Cancer patients with cancer-associated thrombosis (CAT) are at an elevated
risk of recurrent venous thromboembolism (VTE) and of major bleeding while receiving …
risk of recurrent venous thromboembolism (VTE) and of major bleeding while receiving …
A simple method to identify patients on long-term warfarin who may derive the most benefit from new oral anticoagulants
In many countries, new oral anticoagulants are only covered for patients with suboptimal
anticoagulation control on vitamin K antagonists (VKAs). The quality of VKA management is …
anticoagulation control on vitamin K antagonists (VKAs). The quality of VKA management is …
